Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity

Chemotherapeutic agents are generally used as a frontline therapy for non-small cell lung cancer (NSCLC). However, resistance to chemotherapy arises rapidly in NSCLC, and the reasons for chemotherapy resistance have not been fully determined. Here, we found cisplatin, but not paclitaxel and doxorubi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lihui, Liu, Xing, Ren, Yong, Zhang, Jingyuan, Chen, Junli, Zhou, Wenlong, Guo, Wei, Wang, Xiaoxuan, Chen, Huiping, Li, Meng, Yuan, Xiangzhong, Zhang, Xun, Yang, Jingyu, Wu, Chunfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477570/
https://www.ncbi.nlm.nih.gov/pubmed/28406482
http://dx.doi.org/10.1038/cddis.2016.409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477570/
https://www.ncbi.nlm.nih.gov/pubmed/28406482
http://dx.doi.org/10.1038/cddis.2016.409

Ejemplares similares